News search

The findings, published in Cardiovascular Research, show that the right ventricle has greater metabolic resilience than the left during cardiac arrest caused by ventricular fibrillation.

The biomarker MR-proADM improves risk prediction in patients with transthyretin amyloid cardiomyopathy (ATTR-CM) and is associated with greater disease severity, mortality, and heart failure events.

Scientists at the Centro Nacional de Investigaciones Cardiovasculares (CNIC), together with cardiologists from Hospital Universitario Puerta de Hierro and the Spanish cardiovascular disease research network (CIBERCV), report that the new discovery makes it possible to identify high-risk patients early and refer them sooner to specialized heart failure units

A CNIC team has developed an innovative gene therapy strategy for arrhythmogenic right ventricular cardiomyopathy type 5 (ARVC5), a rare and deadly inherited condition that particularly affects young men

The results, published in JACC, suggest that these factors could be used to predict the risk of developing dilated cardiomyopathy and adapt strategies for patient care and disease detection in genetic carriers of the disease

The team led by Dr. Pablo García-Pavía, based at the CNIC and Hospital Puerta de Hierro, has published the first study of a drug able to remove amyloid deposits from the heart

A CNIC study reveals that mutations previously identified in the gene MINDBOMB1 (MIB1) as causing non-compaction cardiomyopathy either provoke this disease or valve defects, depending on their combination with mutations in modifier genes

The findings, published in the Journal of the American College of Cardiology (JACC), will enable physicians to make appropriate treatment adjustments for patients with this disease